Neuropathy Risk Influenced By Racial, Ethnic Disparities
Known risk factors for peripheral neuropathy (PN) may explain the higher prevalence of the condition in non-Hispanic Black adults but not in Hispanic adults in the US, a new study showed. Researchers found that other factors may drive the disparity, including social determinants of health, such as food insecurity and a high percentage of total caloric intake from saturated fatty acids.
METHODOLOGY:
This cross-sectional secondary analysis included more than 8000 US adults (mean age, 61 years; 50% women) who participated in the National Health and Nutrition Examination Survey during 1999-2004.
55% of total participants were non-Hispanic White, 18% were non-Hispanic Black, 24% were Hispanic individuals, and 3% were of other races/ethnicities.
Researchers assessed PN using a monofilament test for reduced sensation in both feet at three plantar locations: first metatarsal head, fifth metatarsal head, and the hallux.
Demographic (age, sex, and race/ethnicity), metabolic (height, weight, waist circumference, systolic and diastolic blood pressure, and levels of high- and low-density lipoprotein cholesterol and A1c), and lifestyle (physical activity and diet) risk factors, as well as social determinants of health (food security, household income, and health insurance), were evaluated.
TAKEAWAY:
Higher age- and sex-adjusted odds of PN were observed in both Black (odds ratio [OR], 1.39) and Hispanic (OR, 1.31) participants than in White participants. Additionally, men had a higher risk for PN than women after age and race adjustment — but not after comprehensive adjustment.
After adjusting for metabolic, lifestyle, and social determinants of health factors, Hispanic individuals maintained a higher likelihood of PN than White individuals (OR, 1.32; P = .001), while Black and White individuals had similar odds of PN (OR, 1.17; P = .17).
Lack of health insurance (OR, 1.49), older age (OR, 1.05), taller height (OR, 1.03), higher levels of A1c (OR, 1.13), and larger waist circumference (OR, 1.01) were all associated with an increased risk for PN.
Among Hispanic individuals specifically, food insecurity (OR, 1.48) and increased percentage of total caloric intake from saturated fatty acids (OR, 1.06) were linked to increased PN risk.
IN PRACTICE:
'After comprehensively adjusting for known risk factors, we found that Black people had similar odds of neuropathy compared to White people, whereas Hispanic people continued to be at an increased likelihood of having neuropathy. Therefore, it is likely that unknown social risk factors exist for this population,' lead study author Evan Lee Reynolds, PhD, Michigan State University, East Lansing, Michigan, said in a press release.
Authors of an accompanying editorial added that the findings 'are a call to action to continue to address the disproportionate exposure to modifiable risk factors in Black and Hispanic populations.'
SOURCE:
The study and the accompanying editorial were published online on July 16 in Neurology. The editorial was authored by Georgette Dib and Nicholas E. Johnson, Virginia Commonwealth University, Richmond, Virginia.
LIMITATIONS:
The study was retrospective, cross-sectional, and partly exploratory in nature and relied on self-reported data. Additionally, some data were missing, monofilament testing may have led to misclassification of PN, and assessment of triglyceride levels was performed only in 53% of participants. Study findings were not generalizable to other racial/ethnic groups or individuals with multiple races/ethnicities.
DISCLOSURES:
Several investigators reported receiving funding from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, Andrea and Lawrence A. Wolfe Research Professorship, Robert E. Nederlander Sr. Program for Alzheimer's Research, Andrea and Lawrence A. Wolfe Brain Health Initiative Fund, A. Alfred Taubman Medical Research Institute, and the NeuroNetwork for Emerging Therapies. One investigator also reported consulting for DynaMed, receiving research and editorial support from the American Academy of Neurology, and providing medicolegal consultations. One of the editorialists reported having various ties with various sources, including pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
an hour ago
- New York Times
As Earth Warms, California Fire Season Is Starting Earlier, Study Finds
California's main wildfire season is starting earlier in the year, and human-caused climate change is a major reason, new research finds. The onset of summertime fire activity in large parts of the state has crept into spring by up to two months since the early 1990s, according to a study published Wednesday in the journal Science Advances. The change has been especially pronounced in the Cascade Range in Northern California, the coastal mountains of Central California and coastal Southern California from Monterey to San Diego. Officials and disaster managers in the state now often speak of fire as a year-round hazard, instead of a seasonal threat. The study rules out two factors that might theoretically be behind the shift: buildups of vegetation and changes in the number of fires ignited, either accidentally or on purpose, by humans. The more important drivers, the researchers found, are the effects of greenhouse warming, including earlier and faster snowmelt and a warmer atmosphere that pulls more moisture out of soil and vegetation. Want all of The Times? Subscribe.
Bloomberg
2 hours ago
- Bloomberg
FTC Sues to Block Edwards LifeSciences Medical Device Deal
The US Federal Trade Commission filed suit Wednesday to block Edwards Lifesciences Corp. from acquiring medical device maker JenaValve Technology Inc. In a complaint filed in Washington federal court, the FTC said the deal would hinder innovation for medical devices used to treat a serious heart condition known as aortic regurgitation, where blood pumped from the heart leaks back into the chamber
